154 related articles for article (PubMed ID: 38236249)
21. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Olencki TE; Tarazi JC; Rosbrook B; Fernandez KC; Lechuga M; Choueiri TK
Lancet Oncol; 2018 Mar; 19(3):405-415. PubMed ID: 29439857
[TBL] [Abstract][Full Text] [Related]
22. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
23. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
24. A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas.
Meehan R; Kummar S; Do K; O'Sullivan Coyne G; Juwara L; Zlott J; Rubinstein L; Doroshow JH; Chen AP
Oncologist; 2018 Nov; 23(11):1269-e125. PubMed ID: 29853657
[TBL] [Abstract][Full Text] [Related]
25. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
[TBL] [Abstract][Full Text] [Related]
26. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors.
Razak AR; Cleary JM; Moreno V; Boyer M; Calvo Aller E; Edenfield W; Tie J; Harvey RD; Rutten A; Shah MA; Olszanski AJ; Jäger D; Lakhani N; Ryan DP; Rasmussen E; Juan G; Wong H; Soman N; Smit MD; Nagorsen D; Papadopoulos KP
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33046621
[TBL] [Abstract][Full Text] [Related]
28. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal Ziv-Aflibercept: Clinical Effects and Economic Impact.
Singh SR; Dogra A; Stewart M; Das T; Chhablani J
Asia Pac J Ophthalmol (Phila); 2017; 6(6):561-568. PubMed ID: 28971631
[TBL] [Abstract][Full Text] [Related]
30. Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
Arance A; de la Cruz-Merino L; Petrella TM; Jamal R; Ny L; Carneiro A; Berrocal A; Márquez-Rodas I; Spreafico A; Atkinson V; Costa Svedman F; Mant A; Khattak MA; Mihalcioiu C; Jang S; Cowey CL; Smith AD; Hawk N; Chen K; Diede SJ; Krepler C; Long GV
J Clin Oncol; 2023 Jan; 41(1):75-85. PubMed ID: 35867951
[TBL] [Abstract][Full Text] [Related]
31. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007419. PubMed ID: 30325017
[TBL] [Abstract][Full Text] [Related]
32. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.
Feun LG; Li YY; Wu C; Wangpaichitr M; Jones PD; Richman SP; Madrazo B; Kwon D; Garcia-Buitrago M; Martin P; Hosein PJ; Savaraj N
Cancer; 2019 Oct; 125(20):3603-3614. PubMed ID: 31251403
[TBL] [Abstract][Full Text] [Related]
33. Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041).
Yamazaki N; Takenouchi T; Fujimoto M; Ihn H; Uchi H; Inozume T; Kiyohara Y; Uhara H; Nakagawa K; Furukawa H; Wada H; Noguchi K; Shimamoto T; Yokota K
Cancer Chemother Pharmacol; 2017 Apr; 79(4):651-660. PubMed ID: 28283736
[TBL] [Abstract][Full Text] [Related]
34. Imatinib mesylate in combination with pembrolizumab in patients with advanced KIT-mutant melanoma following progression on standard therapy: A phase I/II trial and study protocol.
Hirai I; Tanese K; Fukuda K; Fusumae T; Nakamura Y; Sato Y; Amagai M; Funakoshi T
Medicine (Baltimore); 2021 Dec; 100(49):e27832. PubMed ID: 34889232
[TBL] [Abstract][Full Text] [Related]
35. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.
Aggarwal C; Prawira A; Antonia S; Rahma O; Tolcher A; Cohen RB; Lou Y; Hauke R; Vogelzang N; P Zandberg D; Kalebasty AR; Atkinson V; Adjei AA; Seetharam M; Birnbaum A; Weickhardt A; Ganju V; Joshua AM; Cavallo R; Peng L; Zhang X; Kaul S; Baughman J; Bonvini E; Moore PA; Goldberg SM; Arnaldez FI; Ferris RL; Lakhani NJ
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35414591
[TBL] [Abstract][Full Text] [Related]
36. Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.
Baldini C; Danlos FX; Varga A; Texier M; Halse H; Mouraud S; Cassard L; Champiat S; Signolle N; Vuagnat P; Martin-Romano P; Michot JM; Bahleda R; Gazzah A; Boselli L; Bredel D; Grivel J; Mohamed-Djalim C; Escriou G; Grynszpan L; Bigorgne A; Rafie S; Abbassi A; Ribrag V; Postel-Vinay S; Hollebecque A; Susini S; Farhane S; Lacroix L; Parpaleix A; Laghouati S; Zitvogel L; Adam J; Chaput N; Soria JC; Massard C; Marabelle A
J Exp Clin Cancer Res; 2022 Jul; 41(1):217. PubMed ID: 35794623
[TBL] [Abstract][Full Text] [Related]
37. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
Carlino MS; Long GV; Schadendorf D; Robert C; Ribas A; Richtig E; Nyakas M; Caglevic C; Tarhini A; Blank C; Hoeller C; Bar-Sela G; Barrow C; Wolter P; Zhou H; Emancipator K; Jensen EH; Ebbinghaus S; Ibrahim N; Daud A
Eur J Cancer; 2018 Sep; 101():236-243. PubMed ID: 30096704
[TBL] [Abstract][Full Text] [Related]
38. KEYNOTE - D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma.
Long GV; Ferrucci PF; Khattak A; Meniawy TM; Ott PA; Chisamore M; Trolle T; Hyseni A; Heegaard E
Future Oncol; 2022 Oct; 18(31):3473-3480. PubMed ID: 36047545
[TBL] [Abstract][Full Text] [Related]
39. Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B.
Carlino MS; Menzies AM; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Guminski AD; Kefford R; Wu H; Ibrahim N; Homet Moreno B; Long GV
Clin Cancer Res; 2020 Oct; 26(19):5086-5091. PubMed ID: 32605909
[TBL] [Abstract][Full Text] [Related]
40. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
